Lactobacillus Fermentum HEM1036 Composition for LARS and Diarrhea
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for cancer, such as surgery and pharmacological therapies, result in severe side effects like low anterior resection syndrome (LARS), diarrhea, and weight loss, which are not adequately addressed by current methods, particularly those involving Lactobacillus fermentum HEM1036, as they focus on improving gut environment without specific benefits for colorectal cancer patients.
Innovation Solution
A composition comprising Lactobacillus fermentum HEM1036 (KCTC13978BP) as an active ingredient, which regulates short-chain fatty acids and modulates gut microbiota to ameliorate side effects of cancer treatment, including LARS, diarrhea, and weight loss, through pharmaceutical and food compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy agents or targeted agents are used to treat cancer, then cancer cell growth is inhibited, but severe side effects such as diarrhea, LARS, and weight loss occur due to damage to normal intestinal cells
Solution Approach 1:
Lactobacillus fermentum HEM1036 serves as an intermediary substance that mediates between the harmful effects of chemotherapy/targeted agents and the intestinal mucosa. The probiotic bacterium colonizes the gut, produces protective metabolites, and modulates the local immune environment, thereby reducing the direct damage from anticancer drugs to intestinal cells while maintaining treatment efficacy
Solution Approach 2:
The invention converts the harmful damage to intestinal cells caused by chemotherapy and targeted agents into a beneficial opportunity by introducing Lactobacillus fermentum HEM1036. The probiotic exploits the disturbed gut environment to establish colonization, producing short-chain fatty acids and other beneficial substances that actively repair mucosal damage and reduce inflammation, turning the harmful effect into a therapeutic opportunity
2Ease of operation
If Lactobacillus fermentum HEM1036 is used to improve gut environment, then general gut health is enhanced, but specific side effects of cancer treatment such as LARS, diarrhea, and weight loss are not adequately addressed
Solution Approach 1:
The invention specifically modifies key parameters of the gut environment that are critically affected by cancer treatment: increasing production of anti-inflammatory short-chain fatty acids (particularly butyrate), enhancing tight junction protein expression, and modulating specific inflammatory cytokines. These targeted parameter changes address LARS, diarrhea, and weight loss more effectively than general gut health improvement
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces total SCFA and acetate levels, decreases inflammatory markers, improves intestinal permeability and villi length, and enhances quality of life by alleviating symptoms of LARS, diarrhea, and weight loss in cancer patients.
Implementation Method 1
Korean Patent No. 10-2215592 proposed a method for improving gut environment using Lactobacillus fermentum HEM1036
Data Source
AI summary
A composition for ameliorating side effects of cancer treatment, comprising a strain Lactobacillus fermentum HEM1036 (KCTC13978BP) as an active ingredient according to an embodiment of the present disclosure can prevent or treat side effects caused by cancer treatment or intake of anti-cancer agents through regulation of short-chain fatty acids and modulation of gut microbiota, and the composition can be applied to food compositions, health functional food compositions, pharmaceutical compositions, etc. Under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, the Lactobacillus fermentum HEM1036 strain was deposited with the international depositary authority: the Korean Collection for Type Cultures on Oct. 8, 2019, under the Accession Number: KCTC 13978BP.